For The Need Foundation is excited to announce its fifth annual Rocket Launch Day
Rocket Day: Aim for the Stars!
LOS ANGELES, CA, UNITED STATES, January 29, 2025 / EINPresswire.com / -- For The Need Foundation (FTN) is excited to announce its fifth annual Rocket Launch Day and first in Los Angeles for children and their families experiencing homelessness, poverty, or unstable living conditions.
On Saturday, February 8th, 2025, For The Need Foundation will be hosting a Rocket Day for youth at the Rancho Santa Susana Community Center in Simi Valley from 9:50 AM to 2:00 PM PST.
At the event, children and teens get to build and launch model rockets, while learning about the importance of goal setting. . Waste Management We are so thankful that 'WM' has committed to sponsor this amazing event. By the beginning of 2025, For The Need hosted Volunteer Welcome & Training Days for new upcoming volunteers for the organization. This event introduced FTN's new expansion with two locations, their Simi Valley Location (805 Location) and their Los Angeles/Northridge Location (818 Location). The training days were a raging success. This annual event consisted of an introduction of FTN, role-based sessions, access to live-scan background checks, and lunch catered by Chic-Fil-A. A presentation was also given by retired U.S. Army veteran and dedicated leader, Bob Allinder, who shared how to be a critical volunteer and to make the most positive impact to the youth in the Bow & Arrow Mentorship Program. Each volunteer at the end left with a large smile, excited for what is to come in the new year and embraced in the FTN family.
Allie Spaccarelli, Director of FTN, emphasized the importance of volunteer contributions, stating, 'Volunteers are the heart of our organization. Through their dedication and compassion, we can create meaningful opportunities for families and youth facing difficult challenges.' Spaccarelli also shares, 'My favorite part of the event was seeing Mario and Sollas attending the training day, as they started as young Arrows in our program, and are now coming back to be volunteers to make an impact on kids just like them.'
About For the Need Foundation
Founded in 2004, FTN is a non-profit organization dedicated to empowering youth and families experiencing homelessness, poverty, and critical illness. They provide events throughout the year to teach life skills and provide a safe and fun environment where the children and teens can grow in their confidence and connect with positive influences in their community. Recognized as California's Nonprofit of the Year in 2023, FTN continues to transform lives by fostering resilience, hope, and opportunity.
Agency 32 Inc
YouTube
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 days ago
- Business Insider
The infected have evolved in '28 Years Later' — and they're scarier than ever
The "28 Days Later" franchise sees society collapsing after a virus escapes a lab and turns people into zombie-like killers. In "28 Years Later," while people have adapted to survive, the Rage Virus has evolved. Here's how the infected are different in the sequel. Warning: spoilers ahead for "28 Years Later." In " 28 Years Later," the Rage Virus that turned Britain post-apocalyptic in the original movie has evolved, meaning the survivors have new types of the infected to deal with. Spike (Alfie Williams), a 12-year-old boy, is the film's protagonist. He lives on the island of Lindisfarne, cut off from the mainland by the tide, which saves the community from the Rage Virus. His father, Jamie (Aaron Taylor-Johnson), takes him hunting on the mainland as a rite of passage, and Spike learns how dangerous the rest of the country has become after 28 years of the virus spreading. It isn't long before the young boy comes face-to-face with the infected. "There have been evolutions because we didn't want to just stand still with them," the film's director Danny Boyle told IGN in June, referring to the infected. "28 Years Later" introduces "Slow Lows" and "Alphas." On the mainland, Jamie constantly reminds Spike to be vigilant of the infected, and explains that there are "Slow Lows" who crawl on the ground eating bugs. Slow lows are more bloated than the original infected, and their skin is pale and mottled. While they're easier to kill from a distance, their loud screams draw attention. Interestingly, Jamie chooses not to kill one of the Slow Lows when he realizes she's a little girl, and she flees into the undergrowth when he lets her go. But the Slow Lows pale in comparison to the "Alphas," who are much bigger and stronger than the other infected. One Alpha, who is nicknamed Samson (Chi Lewis-Parry), shows off his brute strength by ripping a soldier's head off along with his spine with his bare hands. The Alphas can also withstand getting struck by several arrows without dying, although they can be killed by the large flaming javelins used by the guards on the Lindisfarne gate. Jamie tells Spike that in specific people, the Rage Virus acts like bodybuilding steroids, which appears to make them invulnerable to minor injuries. The Alphas make things difficult for Spike and his mother, Isla (Jodie Comer), when they go looking for a mysterious doctor on the mainland and come across one in the ruins of an old train. Knowing they can't kill an Alpha cranks up the terror in a nail-biting chase sequence.
Associated Press
04-06-2025
- Associated Press
Bullpen Launches Emerging Fund to Champion the Next Generation of Life Sciences Innovators
New investment initiative fuels high-potential startups across biotools, medtech, digital health, and therapeutics. 'BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships.'— Christiaan Engstrom, CEO of Bullpen. BOSTON, MA, UNITED STATES, June 4, 2025 / / -- Bullpen, a trusted community of life sciences dealmakers, today announced the launch of its Bullpen Emerging Fund, a bold initiative designed to back mission-driven startups that are redefining the future of health. Through capital investment, deep mentorship, and access to a close-knit network of expert operators and investors, the fund aims to turn today's early-stage breakthroughs into tomorrow's clinical realities. The Emerging Fund, available to accredited investors, invests in standout companies selected for Bullpen's On-Deck class—founders chosen not only for their science but for their grit, vision, and purpose. The 2025 cohort includes: - Chandima Bandaranayaka, CEO: Precision Quantomics, accelerating drug discovery and personalized pharmacotherapy through high-resolution molecular profiling. - David Mead, CEO: Terra Bioforge, harnessing synthetic biology to streamline biological production and accelerate therapeutic development. - Doug Cohen, CEO: IR Medtek, developing real-time, noninvasive cancer detection technologies that improve early diagnosis and patient outcomes. - Harsha Rajasimha, CEO: Jeeva Clinical Trials, delivering decentralized trial software that enhances patient access, retention, and diversity in clinical research. - Linda Tempelman, CEO: Persista Bio, advancing cell therapy solutions for chronic diseases, including a novel approach to treating Type 1 diabetes. Each of these founders will pitch during Bullpen's 'Money Ball' sessions, June 16–18 at BIO International, to an audience of mission-aligned investors and partners. More than a moment on stage, these pitches represent the culmination of rigorous preparation and the start of a meaningful growth journey. 'Bullpen was built on a simple idea: if you bring the right people together in the right way, the outcomes take care of themselves. BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships that will move this industry forward,' said Christiaan Engstrom, CEO of Bullpen. Further information on the Bullpen Emerging Fund may be obtained from Ray Jordan, managing director, Putnam Insights LLC, and initial investor in the fund through Elmstead Partners LLC. Jordan may be reached at [email protected]. Expert Coaching to Catalyze Success Behind each founder is a seasoned mentor: - Michael Hill, Global Head of Science Innovations, MedTech Head Coach, with a legacy of scaling clinical tools from bench to bedside. - Stella Vnook, CEO of Likarda and Therapies Head Coach, a biotech operator with deep experience in moving science-backed products through commercial launch. - John Bonham-Carter, BioTools Head Coach and angel investor, guiding early-stage science into successful enterprise with strategic insight and operational depth. Throughout the week, Bullpen will host engaging programming across Boston innovation hubs like Portal Innovations, SmartLabs, and EPAM Continuum. Key agenda highlights include: Agenda Highlights Include: - Investor interviews with leaders from Novo Nordisk, Cincytech, DigitalDx, Mayo Clinic, Riverside Partners, and others, with open Q&A in the Press Room following each session. - Thematic forums exploring pivotal industry issues such as: - AI in Healthcare: Exploring how artificial intelligence is reshaping patient care and discovery. - Patient Access: Breaking down barriers to get therapies to those who need them most. - Tech Transfer: Bridging academic science and commercial application. - Rare Disease: Elevating patient voices and rare innovation journeys. - Global Forums: Perspectives from Japan, Korea, Canada, and Australia spotlighting international innovation. - Women in VC and venture insights sessions, giving voice to underrepresented perspectives in capital formation and funding trends. As BIO Week wraps, Bullpen leaves behind more than a schedule, it strengthens a movement. One that champions science, centers people, and dares to do things differently. With the Emerging Fund as its catalyst, Bullpen is helping the next generation of health innovators go further, faster. About Bullpen: Founded on the mantra Find Someone to Help. Repeat., Bullpen is a volunteer-led, member-driven network designed to foster meaningful connections and accelerate innovation in life sciences. With no booths or sales pitches, Bullpen cultivates a space where authentic conversation drives real outcomes. Its members include public and private company leaders, VCs, strategics, accelerators, and non-profit executives dedicated to building the future of health. Media Inquiries: Madelyn De Los Santos Putnam Insights email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
30-05-2025
- Associated Press
Engineered ion channel offers precise, non-invasive control of brain activity
FAYETTEVILLE, GA, UNITED STATES, May 30, 2025 / / -- In a breakthrough advancement for neuroscience, researchers have developed RADICAL, a cutting-edge chemogenetic tool that allows for the precise manipulation of neuronal activity using a synthetic chemical, cyclohexanol ( CHXOL ). Unlike traditional methods that rely on invasive optics or slow-acting G-protein coupled receptors, RADICAL utilizes a modified TRPM8 ion channel to enable rapid and targeted control of calcium influx in neurons. This innovative tool has the potential to advance brain function research and open up new therapeutic possibilities for neurological disorders. Current technologies for controlling neuronal activity—such as optogenetics and chemogenetics—have their limitations. Optogenetics requires invasive light delivery, while chemogenetic systems like DREADDs rely on slow and indirect cellular signaling pathways. Additionally, engineered ligand-gated ion channels, such as those based on nicotinic receptors, can result in unintended interactions with native proteins. These challenges have highlighted the need for a more efficient, non-invasive, and precise method of modulating neuronal excitability. In response to this gap, researchers sought to develop RADICAL, a novel chemogenetic tool that addresses these limitations. In a letter (DOI: 10.1093/procel/pwae048 ) published on September 3, 2024, in Protein & Cell, a team from Zhejiang University unveiled RADICAL, an engineered ion channel activated by cyclohexanol (CHXOL). By introducing specific mutations to the TRPM8 ion channel, they created a system that responds with exceptional sensitivity and specificity to CHXOL. This innovation allows for precise neuronal control without interfering with the brain's native functions, marking a significant step forward in chemogenetics. The key modification in RADICAL was the engineering of the TRPM8 ion channel, which is naturally expressed at low levels in the brain, minimizing potential disruptions to endogenous systems. The team introduced two critical mutations (I846F and I985K) to the TRPM8 ion channel. The I846F mutation restored CHXOL binding, while I985K enhanced voltage sensitivity, enabling robust activation even at hyperpolarizing potentials (-80 mV). Patch-clamp recordings and calcium imaging confirmed the double mutant, TRPM8-I846F-I985K's EC50 of 1.17 mmol/L for CHXOL at depolarizing potentials (+80 mV). In vivo, RADICAL demonstrated its potential: CHXOL administration enhanced fear extinction memory in mice by activating neurons in the infralimbic cortex (IL), and also increased locomotor activity when expressed in astrocytes of the ventral tegmental area (VTA). Importantly, the tool's calcium permeability and minimal cell death risk, as shown in HEK293T cells, suggest its suitability for studying calcium-dependent processes such as learning and memory. Dr. Fan Yang, one of the co-corresponding authors of the study, said: RADICAL represents a major breakthrough in chemogenetics. Its ability to modulate neuronal activity with high precision and minimal off-target effects makes it a versatile tool for both basic neuroscience research and the development of therapeutic interventions. With its non-invasive approach and high specificity, RADICAL has substantial potential in both research and clinical settings. It could enhance our understanding of neurological conditions such as memory disorders, addiction, and mood disorders by providing a precise way to manipulate neuronal circuits. Furthermore, future efforts to miniaturize the tool for adeno-associated virus (AAV) delivery could broaden its applicability in gene therapy. RADICAL's unique combination of speed, specificity, and safety positions it as a powerful platform for next-generation treatments of brain diseases. References DOI 10.1093/procel/pwae048 Original Source URL Funding Information This work was supported by funding from the National Natural Science Foundation of China (32122040 and 31971040 to F.Y.; 32071017 and 31922031 to Y.C.); Zhejiang Provincial Natural Science Foundation of China (LR20C050002 to F.Y.); China Postdoctoral Program for Innovative Talents (BX20230323 to H.Z.); China Postdoctoral Science Foundation (2024M752858 to H.Z.); The Fundamental Research Funds for the Central Universities (226-2022-00227 to F.Y.; 226-2022-00149 to Y.C.); Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions (NYKFKT2019001 to Y.C.); The Fundamental Research Funds for the Central Universities (226-2022-00227 to F.Y.). Lucy Wang BioDesign Research email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
